A Mycobacteriophage-Based Vaccine Platform: SARS-CoV-2 Antigen Expression and Display.

ABSTRACT: The explosion of SARS-CoV-2 infections in 2020 prompted a flurry of activity in vaccine development and exploration of various vaccine platforms, some well-established and some new. Phage-based vaccines were described previously, and we explored the possibility of using mycobacteriophages as a platform for displaying antigens of SARS-CoV-2 or other infectious agents. The potential advantages of using mycobacteriophages are that a large and diverse variety of them have been described and genomically characterized, engineering tools are available, and there is the capacity to display up to 700 antigen copies on a single particle approximately 100 nm in size. The phage body may itself be a good adjuvant, and the phages can be propagated easily, cheaply, and to high purity. Furthermore, the re

SUBMITTER: Freeman KG 

PROVIDER: S-EPMC8704799 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature